ALX Oncology
Danny Ooi is an experienced regulatory affairs professional with a strong background in the biotechnology and pharmaceutical industries, currently serving at ALX Oncology since 2023 in Global Regulatory Affairs focused on large molecules, including antibody-drug conjugates, in the oncology space. Prior to this, Danny held various positions in global regulatory affairs at notable companies such as Amgen, ChemoCentryx, Global Blood Therapeutics, Ultragenyx Pharmaceutical Inc., and Genentech, contributing to the approval of key marketing applications and developing complex regulatory strategies for multiple drug programs. Danny's educational background includes a Ph.D. in Biochemistry and Cell Biology from Harvard University, along with degrees in Biochemistry and Molecular Biology from the University of California, Berkeley, and additional research training and courses in entrepreneurship within the bio-pharmaceutical industry.
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.